CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics - 07/06/26
, Heidi T. May, PhD, MSPH a, Tyler Winslow, BA a, Viet T. Le, PA-C a, c, Leslie Iverson, PA-C a, Tami L. Bair, BS a, Kirk U. Knowlton, MD a, b, Joseph B. Muhlestein, MD a, bHighlights |
• | Whether coronary calcium (CAC) better selects patients for statin therapy is unknown. |
• | CorCal randomized 5,772 primary prevention patients to address this question. |
• | The pooled cohort equation (PCE) was used as the standard of care arm. |
• | Baseline characteristics of the PCE and CAC arms are well balanced. |
• | End-of-Study is planned for April 2026 after over 4.5 years of follow-up. |
ABSTRACT |
Rationale |
Two methods to select statin therapy for primary prevention are the pooled cohort equation (PCE), based on traditional risk factors, and coronary artery calcium (CAC), a patient-level assessment of coronary plaque burden. How well these methods compare in reducing atherosclerotic cardiovascular disease (ASCVD) outcomes is unknown.
Primary Aim |
The CorCal Outcomes trial is designed to evaluate the effectiveness of CAC compared to the PCE as a guide to statin initiation in preventing ASCVD events.
Design |
CorCal Outcomes is a randomized trial comparing CAC to PCE to guide statin initiation in nondiabetic primary prevention patients. The study has a noninferiority design and will utilize a modified per-protocol approach that includes all who completed baseline testing and received a statin recommendation. Here we describe the study design and patient population.
Enrollment |
From October 30, 2019, to March 25, 2025, 75,539 patients were screened via medical record query and randomly invited to participate; 5,772 agreed to be enrolled and were randomized (2886 per arm). Of those, 5,329 completed the necessary testing to be included in the primary analysis (PCE = 2,642 [49.6%], CAC = 2,687 [50.4%]).
Characteristics |
Average age is 64.3 ± 6.8 years, and 51.5% are female. Baseline demographics are well-matched between arms. The recommendations of the Data Safety Monitoring Board of December 9, 2024, and the Study Team’s response are reported.
Current Status |
Enrollment in CorCal Outcomes has resulted in well-balanced characteristics in the 2 arms used to recommend a statin. Based on study progress as of December 2024, the study is projected to end in second quarter of 2026.
Trial Registration |
This study is registered with Clinicaltrials.gov (NCT 03439267).
Le texte complet de cet article est disponible en PDF.Plan
Vol 299
Article 107473- septembre 2026 Retour au numéro
Article précédent
- Direct oral anticoagulation interruption vs continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: Design and rationale of the South Limburg Myocardial Infarction Study Group Trial 2 (SLIM-2)
- Sanne Janssen, Jasper J.P. Luijkx, Wouter Swinnen, Pieter Vriesendorp, Jurrien M. ten Berg, Arnoud W.J. van ‘t Hof, Saman Rasoul, SLIM-2 study group
- Design and rationale of the Radial Access Insertion Sheath Evaluation via the electronic medical record (RAISE-EMR) study
- Binita Shah, Johanna Lerner, Jacob Martin, Byron Patrick Crane, Orwell Andrade, Xiyue Li, Yuhe Xia, Chang Yu, Paul A. Testa, Sunil V. Rao, Pragmatic Randomization Integrated into the Medial Record (PRIME) Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?